Kogenate FS + Advate + Humate-P + Recombinate + Helixate FS

This entry refers to a specific group of Factor VIII (FVIII) replacement therapies—Kogenate FS, Advate, Humate-P, Recombinate, and Helixate FS—that were utilized as interchangeable interventions in a clinical trial protocol sponsored by The Hospital for Sick Children (SickKids). The study, titled Pilot Study of Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A (NCT00108719), evaluated the feasibility of a once-daily low-dose prophylaxis regimen (250 or 500 units per day) using the patient's usual FVIII preparation. Most of these products (Kogenate FS, Advate, Recombinate, and Helixate FS) are recombinant forms of Factor VIII (octocog alfa), while Humate-P is a plasma-derived concentrate containing both Factor VIII and von Willebrand Factor (VWF). These agents work by replacing the deficient or absent clotting factor VIII in patients with Hemophilia A, thereby restoring the intrinsic pathway of the coagulation cascade and preventing spontaneous or traumatic bleeding episodes.

Brand names

Helixate FS

Other names

octocog alfaAntihemophilic Factor (Recombinant)Antihemophilic Factor/von Willebrand Factor Complex (Human)